CASI PHARMACEUTICALS INC.

🇰🇾Cayman Islands

Country: 🇰🇾Cayman Islands

Ownership: Public

Employees: 243

Market Cap: $100.6M

Website: http://www.casipharmaceuticals.com

Clinical Trials

Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: MKC-1

First Posted Date: 2007-12-06

Last Posted Date: 2011-08-04

Lead Sponsor: CASI Pharmaceuticals, Inc.

Target Recruit Count: 33

Registration Number: NCT00568646

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies

Phase 1

Completed

Conditions: Hematological Malignancies
Myelodysplasia
Agnogenic Myeloid Metaplasia

Interventions: Drug: MKC-1

First Posted Date: 2007-07-25

Last Posted Date: 2009-05-05

Lead Sponsor: CASI Pharmaceuticals, Inc.

Target Recruit Count: 30

Registration Number: NCT00506402

Locations: 🇨🇦
Princess Margaret Hospital, Toronto, Canada

Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)

Phase 2

Completed

Conditions: Recurrent Glioblastoma Multiforme

Interventions: Drug: Panzem NCD
Drug: Temozolomide

First Posted Date: 2007-06-01

Last Posted Date: 2008-11-25

Lead Sponsor: CASI Pharmaceuticals, Inc.

Target Recruit Count: 15

Registration Number: NCT00481455

Locations: 🇺🇸
The Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, United States

Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma

Phase 2

Completed

Conditions: Metastatic Renal Cell Carcinoma

Interventions: Drug: Panzem® NCD
Drug: Sunitinib Malate

First Posted Date: 2007-03-07

Last Posted Date: 2011-08-04

Lead Sponsor: CASI Pharmaceuticals, Inc.

Target Recruit Count: 82

Registration Number: NCT00444314

Locations: 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States

Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Advanced Cancer
Non-Small Cell Lung Cancer

Interventions: Drug: MKC-1
Drug: pemetrexed

First Posted Date: 2006-12-06

Last Posted Date: 2012-01-20

Lead Sponsor: CASI Pharmaceuticals, Inc.

Target Recruit Count: 27

Registration Number: NCT00408226

Locations: 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

and more 1 locations

Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

First Posted Date: 2006-11-16

Last Posted Date: 2008-11-25

Lead Sponsor: CASI Pharmaceuticals, Inc.

Target Recruit Count: 18

Registration Number: NCT00400348

Locations: 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States

Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Panzem® NCD

First Posted Date: 2006-11-01

Last Posted Date: 2008-11-25

Lead Sponsor: CASI Pharmaceuticals, Inc.

Target Recruit Count: 21

Registration Number: NCT00394810

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

and more 1 locations

A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors

Phase 2

Completed

Conditions: Carcinoid Tumor

Interventions: Drug: Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)

First Posted Date: 2006-05-22

Last Posted Date: 2010-03-10

Lead Sponsor: CASI Pharmaceuticals, Inc.

Target Recruit Count: 31

Registration Number: NCT00328497

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: MKC-1

First Posted Date: 2006-03-24

Last Posted Date: 2009-06-03

Lead Sponsor: CASI Pharmaceuticals, Inc.

Target Recruit Count: 65

Registration Number: NCT00306631

Locations: 🇺🇸
IUPUI, Indianapolis, Indiana, United States

Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma

Phase 2

Completed

Conditions: Recurrent Glioblastoma Multiforme

First Posted Date: 2006-03-24

Last Posted Date: 2008-12-10

Lead Sponsor: CASI Pharmaceuticals, Inc.

Target Recruit Count: 27

Registration Number: NCT00306618

Locations: 🇺🇸
The Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy